[1]
Li J, Chen F, Zhang Q, et al. Genome-wide Network-assisted Association and Enrichment Study of Amyloid Imaging Phenotype in Alzheimer’s Disease. Curr Alzheimer Res 16(13): 1163-74. (2019)
[2]
Patel H, Hodges AK, Curtis C, Lee SH, Troakes C, Dobson RJB, et al. Transcriptomic analysis of probable asymptomatic and symptomatic Alzheimer brains. Brain Behav Immun 80: 644-56. (2019)
[3]
Hong G, Zeng P, Li N, Cai H, Guo Y, Li X, et al. A Qualitative Analysis Based on Relative Expression Orderings Identifies Transcriptional Subgroups for Alzheimer’s Disease. Curr Alzheimer Res 16(13): 1175-82. (2019)
[4]
Wei SC, Wei W, Peng WJ, Liu Z, Cai ZY, Zhao B. Metabolic alterations in the outer membrane vesicles of patients with Alzheimer’s disease: an LC-MS/MS -based metabolomics analysis. Curr Alzheimer Res 16(13): 1183-95. (2019)
[5]
Zeng FF, Liu J, He H, Gao XP, Liao MQ, Yu XX, et al. Association of PICALM gene polymorphisms with Alzheimer’s disease: Evidence from an updated meta-analysis. Curr Alzheimer Res 16(13): 1196-205. (2019)
[6]
Parikh I, Fardo DW, Estus S. Genetics of PICALM expression and Alzheimer’s disease. PLoS One 9(3)e91242 (2014)
[7]
Li Z, Xiong Z, Manor LC, Cao H, Li T. Integrative computational evaluation of genetic markers for Alzheimer’s disease. Saudi J Biol Sci 25(5): 996-1002. (2018)
[8]
Lu TT, Wan C, Yang W, Cai Z. Role of Cdk5 in Amyloid-beta Pathology of Alzheimer’s Disease. Curr Alzheimer Res 16(13): 1206-15. (2019)
Related Books
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research-Dementia
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Article Metrics
13